Earlier clinical experience with [177Lu]Lu-PSMA in recurrent GBM has demonstrated feasibility and safety, with stabilisation of disease in pre-treated patients, but requires validation in larger series [98,99]. The gene discussed is FOLH1; the disease is glioblastoma.